More about

Wet Age-Related Macular Degeneration

News
October 25, 2023
1 min read
Save

ANX007 for geographic atrophy receives priority medicine designation from EMA

ANX007 for geographic atrophy receives priority medicine designation from EMA

The European Medicines Agency granted priority medicine designation to ANX007 for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Annexon Biosciences.

News
September 30, 2023
3 min watch
Save

VIDEO: Sozinibercept shows good results in combination with VEGF-A inhibitors

VIDEO: Sozinibercept shows good results in combination with VEGF-A inhibitors

SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Dante J. Pieramici, MD, overviews pharmacokinetics and safety data for sozinibercept.

News
September 22, 2023
4 min read
Save

What is your approach for treating GA with concomitant neovascular AMD?

What is your approach for treating GA with concomitant neovascular AMD?

The clinical trials have purposefully strict inclusion and exclusion criteria to control the variables that might affect the outcomes of an intervention.

News
September 12, 2023
1 min read
Save

EyePoint reports positive interim safety data for diabetic retinopathy, wet AMD treatment

EyePoint reports positive interim safety data for diabetic retinopathy, wet AMD treatment

EyePoint Pharmaceuticals has announced positive interim masked safety data for its investigational EYP-1901 for treatment of moderate to severe nonproliferative diabetic retinopathy and wet age-related macular degeneration.

News
August 31, 2023
1 min read
Save

FDA does not approve biologics license application for ONS-5010 for wet AMD treatment

FDA does not approve biologics license application for ONS-5010 for wet AMD treatment

The FDA issued a complete response letter noting its rejection of the biologics license application for ONS-5010 for the treatment of wet age-related macular degeneration, according to a press release from Outlook Therapeutics.

News
August 30, 2023
1 min read
Save

AMD highlights from ASRS: Positive real-world faricimab data, gene therapy and more

AMD highlights from ASRS: Positive real-world faricimab data, gene therapy and more

The American Society of Retina Specialists annual meeting featured study results and research in age-related macular degeneration.

News
August 23, 2023
1 min read
Save

Suprachoroidal axitinib for wet AMD safe in phase 1/2a trial

Suprachoroidal axitinib for wet AMD safe in phase 1/2a trial

SEATTLE — Suprachoroidal axitinib had an “excellent” safety profile at all doses in the treatment of wet age-related macular degeneration, with early signs of durability and reduction in treatment burden, a speaker said here.

News
August 16, 2023
1 min read
Save

Phase 3 study meets primary efficacy endpoint for aflibercept biosimilar in wet AMD

Phase 3 study meets primary efficacy endpoint for aflibercept biosimilar in wet AMD

An aflibercept biosimilar demonstrated positive results in the treatment of wet age-related macular degeneration in a phase 3 study, according to a press release from Sandoz.

News
August 15, 2023
1 min read
Save

PULSAR trial shows efficacy of aflibercept 8 mg in wet AMD with long treatment intervals

PULSAR trial shows efficacy of aflibercept 8 mg in wet AMD with long treatment intervals

SEATTLE — The PULSAR trial in wet age-related macular degeneration demonstrated that aflibercept 8 mg administered every 12 or 16 weeks is noninferior in vision gains compared with aflibercept 2 mg every 8 weeks.

News
August 11, 2023
1 min read
Save

PULSAR: Extended dosing intervals for wet AMD maintained at 2 years with aflibercept 8 mg

PULSAR: Extended dosing intervals for wet AMD maintained at 2 years with aflibercept 8 mg

The majority of patients with wet age-related macular degeneration who received aflibercept 8 mg maintained extended dosing intervals through 2 years in a pivotal trial, according to a press release from Regeneron.

View more